Bayer

Stivarga
Pharma

Bayer sells cancer drug Stivarga to Grünenthal for up to $431M

Patent protection for Stivarga is expected to last until 2029 in the EU and 2030 in the U.S., but has already expired in China.
Angus Liu Sep 21, 2026 10:20am
FDA approved stamp regulations yes go

Bayer’s Kerendia scores FDA nod for CKD in Type 1 diabetes

Sep 17, 2026 2:06pm
Bayer cross

FDA christens Hyrnuo a first-line option for rare lung cancer

Sep 9, 2026 4:33pm
Bayer Bill Anderson

Bayer CEO Anderson sticking out firm's revitalization scheme

Aug 4, 2026 10:40am
Bayer

Bayer scores €3B capital equity infusion in deal with Apollo

Jul 10, 2026 11:31am
fact fake magnifying glass truth

Drugmaker caught faking doctors’ petition to evade China price cut

Jul 8, 2026 11:31am